HGHRX: Hartford Healthcare R3

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

HGHRX Hartford Healthcare R3


Profile

HGHRX - Profile

Vitals

  • YTD Return 29.5%
  • 3 Yr Annualized Return 7.4%
  • 5 Yr Annualized Return 0.3%
  • Net Assets $1.36 B
  • Holdings in Top 10 39.3%

52 WEEK LOW AND HIGH

$40.09
$29.00
$40.09

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.61%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 27.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $0
  • IRA $0

Fund Classification


Distributions

  • YTD Total Return 29.5%
  • 3 Yr Annualized Total Return 12.8%
  • 5 Yr Annualized Total Return 7.4%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.72%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    The Hartford Healthcare Fund
  • Fund Family Name
    Hartford Mutual Funds
  • Inception Date
    Dec 22, 2006
  • Shares Outstanding
    N/A
  • Share Class
    Retirement
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Ann C. Gallo

Fund Description

Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP ("Wellington Management"). The fund takes a broad approach to investing in the health care sector. It may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors.


Get Updates About HGHRX

Sign up for Advisor Access to receive email updates about HGHRX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

HGHRX - Performance

Return Ranking - Trailing

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
YTD 29.5% 9.8% 45.5% 15.38%
1 Yr 13.2% -15.7% 25.8% 31.62%
3 Yr 7.4%* -11.8% 28.3% 57.80%
5 Yr 0.3%* -11.2% 15.4% 54.81%
10 Yr 10.4%* -1.8% 19.0% 40.91%

* Annualized

Return Ranking - Calendar

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
2018 -10.4% -25.3% 21.5% 74.77%
2017 15.3% -10.8% 43.9% 54.13%
2016 -17.2% -31.6% 6.9% 61.32%
2015 -1.6% -20.4% 13.8% 45.63%
2014 18.0% -5.8% 31.5% 43.75%

Total Return Ranking - Trailing

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
YTD 29.5% 9.8% 45.5% 15.38%
1 Yr 13.2% -15.7% 33.7% 36.75%
3 Yr 12.8%* -11.8% 28.3% 38.53%
5 Yr 7.4%* -11.2% 17.2% 32.69%
10 Yr 14.2%* -1.8% 19.0% 35.23%

* Annualized

Total Return Ranking - Calendar

Period HGHRX Return Category Return Low Category Return High Rank in Category (%)
2018 -10.4% -25.3% 22.2% 75.68%
2017 21.3% -10.8% 45.8% 44.95%
2016 -8.8% -26.4% 8.7% 31.13%
2015 12.1% -16.6% 15.2% 14.56%
2014 26.0% -5.8% 36.7% 45.83%

NAV & Total Return History


Holdings

HGHRX - Holdings

Concentration Analysis

HGHRX Category Low Category High HGHRX % Rank
Net Assets 1.36 B 3.25 M 47.5 B 34.65%
Number of Holdings 103 26 388 24.41%
Net Assets in Top 10 501 M 857 K 17.4 B 40.16%
Weighting of Top 10 39.27% 21.3% 77.1% 58.27%

Top 10 Holdings

  1. Abbott Laboratories 4.90%
  2. Pfizer Inc 4.76%
  3. Bristol-Myers Squibb Company 4.55%
  4. Medtronic PLC 4.48%
  5. Thermo Fisher Scientific Inc 3.79%
  6. Anthem Inc 3.71%
  7. Eli Lilly and Co 3.50%
  8. Boston Scientific Corp 3.43%
  9. AstraZeneca PLC ADR 3.08%
  10. UnitedHealth Group Inc 3.06%

Asset Allocation

Weighting Return Low Return High HGHRX % Rank
Stocks
97.80% 90.21% 103.54% 58.27%
Cash
2.20% 0.00% 9.79% 29.92%
Preferred Stocks
0.00% 0.00% 1.08% 45.67%
Other
0.00% -27.41% 5.17% 59.06%
Convertible Bonds
0.00% 0.00% 1.54% 39.37%
Bonds
0.00% 0.00% 20.60% 39.37%

Stock Sector Breakdown

Weighting Return Low Return High HGHRX % Rank
Healthcare
97.80% 56.22% 99.75% 25.98%
Utilities
0.00% 0.00% 0.00% 34.65%
Technology
0.00% 0.00% 16.35% 62.20%
Real Estate
0.00% 0.00% 5.81% 40.16%
Industrials
0.00% 0.00% 2.40% 41.73%
Financial Services
0.00% 0.00% 5.93% 48.03%
Energy
0.00% 0.00% 0.43% 37.80%
Communication Services
0.00% 0.00% 1.02% 38.58%
Consumer Defense
0.00% 0.00% 34.83% 40.16%
Consumer Cyclical
0.00% 0.00% 10.49% 40.16%
Basic Materials
0.00% 0.00% 1.94% 55.12%

Stock Geographic Breakdown

Weighting Return Low Return High HGHRX % Rank
US
80.16% 58.61% 99.93% 56.69%
Non US
17.64% 0.00% 40.52% 34.65%

Expenses

HGHRX - Expenses

Operational Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.61% 0.10% 4.94% 33.33%
Management Fee 0.85% 0.09% 1.30% 73.23%
12b-1 Fee 0.50% 0.00% 1.00% 56.94%
Administrative Fee 0.20% 0.01% 0.40% 76.79%

Sales Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HGHRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 27.00% 0.00% 341.00% 8.47%

Distributions

HGHRX - Distributions

Dividend Yield Analysis

HGHRX Category Low Category High HGHRX % Rank
Dividend Yield 0.00% 0.00% 3.95% 44.88%

Dividend Distribution Analysis

HGHRX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Monthly Annually

Net Income Ratio Analysis

HGHRX Category Low Category High HGHRX % Rank
Net Income Ratio -0.72% -2.24% 2.12% 79.49%

Capital Gain Distribution Analysis

HGHRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

HGHRX - Fund Manager Analysis

Managers

Ann C. Gallo


Start Date

Tenure

Tenure Rank

May 01, 2000

19.59

19.6%

Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.

Robert L. Deresiewicz


Start Date

Tenure

Tenure Rank

May 01, 2000

19.59

19.6%

Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.

Jean M. Hynes


Start Date

Tenure

Tenure Rank

May 01, 2000

19.59

19.6%

Jean M. Hynes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management and securities analysis for the health science portion of the Fund since August 2003. Jean holds a BA in economics from Wellesley College (1991). She joined Wellington Management upon her graduation. She holds the Chartered Financial Analyst designation, and is a member of the CFA Institute and the Boston Security Analysts Society.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.22 9.78 19.59